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Abstract
Stable gastric pentadecapeptide BPC 157 was previously used to ameliorate wound heal-
ing following major surgery and counteract diclofenac toxicity. To resolve the increasing
early risks following major massive small bowel resectioning surgery, diclofenac combined
with nitric oxide (NO) system blockade was used, suggesting therapy with BPC 157 and the
nitric oxide synthase (NOS substrate) L-arginine, is efficacious. Immediately after anasto-
mosis creation, short-bowel rats were untreated or administered intraperitoneal diclofenac
(12 mg/kg), BPC 157 (10 μg/kg or 10 ng/kg), L-NG-nitroarginine methyl ester (L-NAME, 5
mg/kg), L-arginine (100 mg/kg) alone or combined, and assessed 24 h later. Short-bowel
rats exhibited poor anastomosis healing, failed intestine adaptation, and gastrointestinal,
liver, and brain lesions, which worsened with diclofenac. This was gradually ameliorated by
immediate therapy with BPC 157 and L-arginine. Contrastingly, NOS-blocker L-NAME
induced further aggravation and lesions gradually worsened. Specifically, rats with surgery
alone exhibited mild stomach/duodenum lesions, considerable liver lesions, and severe
cerebral/hippocampal lesions while those also administered diclofenac showed widespread
severe lesions in the gastrointestinal tract, liver, cerebellar nuclear/Purkinje cells, and cere-
brum/hippocampus. Rats subjected to surgery, diclofenac, and L-NAME exhibited the men-
tioned lesions, worsening anastomosis, and macro/microscopical necrosis. Thus, rats
subjected to surgery alone showed evidence of deterioration. Furtheremore, rats subjected
to surgery and administered diclofenac showed worse symptoms, than the rats subjected to
surgery alone did. Rats subjected to surgery combined with diclofenac and L-NAME
showed the worst deterioration. Rats subjected to surgery exhibited habitual adaptation of
the remaining small intestine, which was markedly reversed in rats subjected to surgery and
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diclofenac, and those with surgery, diclofenac, and L-NAME. BPC 157 completely amelio-
rated symptoms in massive intestinal resection-, massive intestinal resection plus diclofe-
nac-, and massive intestinal resection plus diclofenac plus L-NAME-treated short bowel
rats that presented with cyclooxygenase (COX)-NO-system inhibition. L-arginine amelio-
rated only L-NAME-induced aggravation of symptoms in rats subjected to massive intestinal
resection and administered diclofenac plus L-NAME.
Introduction
Massive small bowel resection is imperative in the management of several pathological condi-
tions and is associated with high operative mortality [1] and extended post-operative analgesic
use [2].
Therefore, we focused on the early disturbances that occur 24 h after massive intestinal
resection (only 20% of the small intestine was retained in rats) including poor anastomosis and
failed adaptation of the retained intestine, as well as concomitant occurrence of gastrointesti-
nal, liver, and brain lesions that have been poorly described to date. Then, we focused on mas-
sive resectioning with diclofenac administration and the possible noxious stimuli that could
further aggravate these particularly dysfunctions including a nitric oxide synthase (NOS)-
blocker and L-NG-nitroarginine methyl ester (L-NAME) administered alone or together, after
short-bowel formation. In particular, we considered the possible extended analgesic use [2]
and also focused on potential adjunct therapy including stable gastric pentadecapeptide BPC
157 and the NOS-substrate L-arginine [3,4], and their underlying mechanisms. The cyclooxy-
genase (COX) and nitric oxide (NO) systems are not considered to play critical roles after mas-
sive small intestine resection, particularly in the initial period.
Counteracting nonsteroidal anti-inflammatory drug (NSAID) toxicity [4–9] particularly,
diclofenac-induced [4,7], the stable gastric pentadecapeptide BPC 157 might rescue short-
bowel rats in the long-term after massive small intestine resection and improve intestinal anas-
tomosis healing. In addition, it may interact with the NO-system in different animal models
and species [3,10]. Consistent with its initial clinical application [11,12] BPC 157 was originally
used as an anti-ulcer peptide and thought to be a novel mediator of Robert’s cytoprotection. It
is stable in human gastric juice and was designated as a novel mediator of cytoprotection [13].
It has been administered in inflammatory bowel disease [11,12], a multiple sclerosis trial [14],
and was recently reviewed [3,4,10–14]. Finally, BPC 157 shows beneficial effects on the NO-
system and, thereby, affects gastrointestinal lesions [15,16], fistulas [17–20], blood pressure
[15,16], and arrhythmias [16,21].
Furthermore, BPC 157 induced wound healing including in blood vessels [9,10,22–29] and
stimulation of the early growth response 1 (egr-1) gene and its co-repressor nerve growth factor
1-A binding protein-2 (naB2) [26]. These factors are also responsible for cytokine and growth
factor generation and, therefore, early extracellular matrix (collagen) blood vessel formation
[26]. On the other hand, studies have correlated the beneficial effects of BPC 157 with the acti-
vation of a cellular focal adhesion kinase (FAK)-paxillin signal pathway and subsequently dem-
onstrated that it dose- and time-dependently increased the expression of the growth hormone
receptor, Janus kinase 2 (JAK-2) downstream in the associated signal pathway [27–29]. Fur-
thermore, we hypothesized that the massive small bowel resection early state and concomitant
gastrointestinal, liver, and brain lesions may be a particular COX-NO-system inhibition phe-
nomenon. Therefore, in this study we investigated whether BPC 157 and L-arginine [3,4] could
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act as a specific therapeutic combination and alleviate the initial symptoms as well as modulate
the NSAID post-surgery administration and NO-system involvement.
Materials and Methods
Animals
Study protocols were conducted in male laboratory rats; strain Albino Wistar, body weight
between 250–280 g for males, 14 weeks old, in house bred—animal facility Pharmacology-
School of Medicine, Zagreb Croatia. Animal facility registered by Directorate of Veterinary;
Reg. No: HR-POK-007. Laboratory rats were acclimated for 5 days and randomly assigned to
their respective treatment group. Laboratory animals were housed in PC cages in conventional
laboratory conditions at the temperature of 20–24°C, relative humidity of 40-70% and noise
level 60 DCB. Each cage was identified following dates: number of study, group, dose, number
and sex of each animal. Fluorescent lighting provided illumination 12 hours per day. Standard
GLP diet and fresh water was provided ad libitum. Animal care was in compliance with SOPs
of Pharmacology Animal facility; the European convention for the protection of vertebrate ani-
mals used for experimental and other scientific purposes (ETS 123).
Ethical principles of the study ensured compliance with European Directive 010/63/E, the
Law on Amendments to Animal Protection Act (Official Gazette 37/13, the Animal Protection
Act (official Gazette 135/06), Ordinance on the protection of animals used for scientific pur-
poses (Official Gazette 55/13), FELASA recommendations and recommendations of the Ethics
Committee School of Medicine, University of Zagreb. All experiments received specific
approval from the Local Ethics Committee at the School of Medicine (University of Zagreb,
Zagreb, Croatia). We randomly assigned at least 10 rats per experimental group and period for
all experiments.
Surgery
Using previously described methods [1], a massive small bowel resection was performed (80%
removed) under deep anesthesia. The peritoneal cavity was penetrated through a 4-cm midline
incision and a single-layer jejunoileal anastomosis performed using 7–0 polypropylene (Pro-
lene, Ethicon, Hamburg, Germany) continuous sutures, and the abdominal incision was closed
using 3–0 silk sutures.
Drugs
The medication, without carrier or peptidase inhibitor, included BPC 157 (a partial sequence
of the human gastric juice protein BPC, freely soluble in saline and water at pH 7.0). It was pre-
pared as a peptide with 99% purity (high-performance liquid chromatography, HPLC; main
impurity, 1-des-Gly peptide, GEPPPGKPADDAGLV, MW 1419; Diagen, Ljubljana, Slovenia).
Diclofenac (Voltaren, Pliva) was prepared as described before [1,4–8,30]. Diclofenac (12 mg/
kg) was administered once intraperitoneally, immediately after anastomosis creation. BPC 157
(10 μg/kg and 10 ng/kg), L-NAME (5 mg/kg), and L-arginine (100 mg/kg) were administered
per se or combined with each other while controls were administered equivolume saline (5
mL/kg) intraperitoneally.
Diazepam (5mg/kg b.w. i.p.) and sodium thiopental (5mg/kg b.w. i.p.) were used for anaes-
thesia, while solely sodium thiopental (20mg/kg b.w. i.p) was used for euthanasia.
Due all animals were sacrificed 24 hours after anaesthesia and surgical procedure, we moni-
tored them through those 24 hours and did not administrate any additional drugs to provide
additional analgesia.
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Evaluations
The evaluations (24 h after massive small bowel resection) included a macroscopic assessment,
histological examination, and biochemical testing performed as described previously [1,3–
8,14,30] in the following sections. The evaluations included all animals underwent experiments
due there were not any unexpected deaths of animals due to either anaesthesia/medication or
surgical procedure.
Anastomosis assessment
The macroscopy and microscopy assessments were carried out as previously described
[1,14,30]. Briefly, the gross anastomosis presentation was scored as 1, total dehiscence; 2, par-
tial dehiscence; 3, edema; and 4, normal anastomosis. The adhesion presentation was scored
from 0–7: 0, no adhesion; 1, thin adhesions covering less than half of the anastomosis; 2, prom-
inent adhesions on more than half of the anastomosis; 3, exaggerated adhesions with whole
anastomosis; 4, the mesenterial part of the small bowel was also involved; 5, neighboring small
intestine loop also involved; 6, numerous neighboring small intestine loops involved; and 7,
neighboring loops, the stomach, and were liver ‘packed’. Intestinal passage obstruction [30]
was scored from 0–3 according to the loop diameter ratios close to the anastomosis. In other
words, an oral loop diameter of 2 cm/aboral loop diameter of 2 cm = 1 denoted a normal pas-
sage (score 0); ratios 1–1.33, mild obstruction (score 1); 1.33–1.66, moderate obstruction (score
2); and< 1.66, severe obstruction (score 3).
For microscopy assessment [1,14,30], the tissue specimens were immediately fixed in buff-
ered formalin (pH 7.4) for 24 h, dehydrated, and then embedded in paraffin wax. The samples
were stained with hematoxylin and eosin (H&E, for evaluation of epithelization, necrosis,
edema, granulation tissue, and inflammatory cells) and examined in a blinded fashion. For the
morphometrical analysis, special software programs SFORM and ISSA (Vamstec, Zagreb, Cro-
atia) were used. Five high power fields (HPFs) were randomly selected for the analysis. We
determined the edema scores as none (0); gap not exceeding one-third or one thickness of mus-
cle layer area (1); gap exceeding one thickness but not two thicknesses of muscle layer area (2);
and gap of two thicknesses of the muscle layer area (3). Necrosis and granulation tissue forma-
tion were scored as follows: none (0); present on less than 20% of the anastomosis area (1);
present on 20–60% of the anastomosis area (2); and present on more than 60% of the anasto-
mosis area (3). Morphometrical analyses were used to determine the total number of inflam-
matory cells, reticulin, and collagen present (expressed as a percentage of the total area).
To assess adaptation of the small intestine, we used previously described methods [1] to
measure a region 3-cm proximal to 3-cm distal to the anastomosis, villus height (from villus
base to villus tip), crypt depth (from crypt base to villus base), and muscle thickness (inner, cir-
cular, and outer, longitudinal muscular layer) in blinded fashion. We used an objective
mounted micrometer (200×magnification) and optical microscope at 10× and 100× magnifica-
tion. Data for the mucosal height (villus height and depth) and muscle thickness (inner, circu-
lar, and outer, longitudinal, muscular layer) are averages of eight measurements for each
animal. In accordance with previous findings villus height, crypt depth, inner circular muscle
thickness, and outer longitudinal muscular layer measurements of 307.4 ± 13, 145.2 ± 14.7,
22.6 ± 5.8, and 12.5 ± 4.6 μm, respectively in the ileum and 414.6 ± 14.4, 165.2 ± 12.3, 27.1
±6.7, 15.5 ± 4.0 μm, respectively in the jejunum were considered normal [1].
Gastrointestinal lesion assay
The gastric, duodenal, and small and large intestinal lesions were determined as described pre-
viously [1,3–8,14,30]. Injury severity was assessed immediately after euthanasia. The sum of
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the longest lesion diameters was assessed as described previously [1,3–8,14,30], and tissues
were processed for routine microscopic analysis as described previously [1,3–8,14,30].
Liver lesions
The liver tissue samples were immediately placed in 10% neutral buffered formalin for 24 h
and subsequently embedded in paraffin. The H&E stained sections were analyzed in three
high-power fields. The number of nuclei was counted and their diameters measured using the
ISSA program (Vamstec, Zagreb, Croatia) and the number of binucleated cells was also
counted. Microvesicular steatosis was scored from 1–3: 1, less than 20% of hepatocytes showed
microvesicular steatosis; 2, 20–60% of hepatocytes showed microvesicular steatosis; and 3, over
60% of hepatocytes showed microvesicular steatosis. Parenchymal necrosis, eosinophilic cyto-
plasm, pyknotic nuclei, and conspicuous nucleoli were scored semiquantitatively as follows: 0,
showed no changes; 1, minimum; 2, moderate; and 3, maximum changes [5–7].
Bilirubin and enzyme activity
To determine the serum levels of aspartate transaminase (AST), alanine transaminase (ALT,
IU/L), and total bilirubin (μmol/L), blood samples were collected immediately after euthanasia
and centrifuged for 15 min at 3000 rpm. All tests were performed using an Olympus AU2700
analyzer with original test reagents (Olympus Diagnostica, Lismeehan, Ireland) [5–7].
Brain lesions
As previously described [5–7] the whole brain was fixed in 10% neutral buffered formalin for 2
days, grossly inspected, and then consecutive 5-μm coronal sections were cut. Brain slabs were
dehydrated in graded ethanol, embedded in paraffin, and the blocks were cut into 5-μm-thick
sections, which were subsequently deparaffinized in xylene, rehydrated in graded ethanol, and
H&E stained. The intensity and distribution of brain lesions (swollen or damaged hypoxic neu-
rons) and edema were described and evaluated semi-quantitatively with 0 indicated no
changes. The lesions were then scored on a 0–3 scale, edema (1, weak diffuse, perifocal or both;
2, moderate; 3, intense and generalized) and 0–4, ballooned or red neurons (1, 2, 3, and 4
were< 5, 5–30, 30–50, and>50% red neurons, respectively. It is noteworthy to mention that
neurons are particularly vulnerable to damage from hypoxia, which causes distinctive histolog-
ical ischemic changes including pronounced cytoplasmic eosinophilia (red neurons), collapse
of cytoplasm with accentuated pericellular spaces, and pyknotic nuclei with indistinct nucleoli.
In addition, ischemia produced ultrastructural cellular necrotic changes with breaks in the
nuclear and cell membranes and flocculent densities in the mitochondria.
Statistical analysis
Nonparametric Kruskal-Wallis and Mann–Whitney U-tests were used for the statistical analy-
sis. The number of rats presenting with epithelization or newly formed muscle was compared
using Fisher’s two-tailed exact probability test. Values of P< 0.05 were considered statistically
significant.
Results
Post-surgical examination (24 h) revealed the beneficial effects of BPC 157(Tables 1 and 2, Figs
1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11) on the poor anastomosis associated with the massive small
intestine resectioning, and initial adaptation attempts of the remaining intestine (Table 1 and
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Figs 1 and 2). The lesions presented rapidly in the upper gastrointestinal tract (Fig 3), liver
(Figs 4 and 5), and brain (Table 2 and Fig 6).
Then, assessment of symptom aggravation (Tables 1 and 2, Figs 1, 3, 5, and 7–10) revealed
early deterioration following administration of diclofenac, with widespread lesions in the
whole gastrointestinal tract. In addition, a higher level of deterioration occurred when
Table 1. Microscopy and gross anastomosis assessment (min/med/max)(days) in short bowel-rats and in short bowel-rats that received diclofe-
nac (12 mg/kg intraperitoneally).
Microscopy and gross anastomosis assessment
Parameters
assessed
Massive small bowel
resection
Massive small bowel resection
Diclofenac
saline BPC157 μg saline BPC157 μg BPC
157 ng
L-NAME L-arg L-NAME
+L-arg
L-NAME
+BPC
157μg
L-arg
+BPC
157 μg
L-NAME+L-
arg+BPC
157μg
Edemascored 0–3 3/3/3 1/1/1* 3/3/3 1/1/1* 1/1/1* 3/3/3 2/2/2* 3/3/3 1/1/2* 1/1/1* 1/1/2*
Granulationscored
0–3
0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0 0/0/0
Necrosis scored 0–3 2/2/2 1/1/1* 3/3/3 2/2/2 2/2/2 3/3/3* 2/3/3 3/3/3* 2/2/2 2/2/2 2/2/2
Number of
inﬂammatory cells
150/
169/
185
120/135/
154*
170/
189/
205
135/148/
164*
145/
159/
172*
190/219/
225*
160/
180/
195
180/189/
195*
143/153/
169*
133/140/
163*
130/158/
170*
Intestinal obstruction
scored 0–3
1/1/1 0/0/0* 1/1/1 0/0/0* 0/0/0* 1/1/2 1/1/1 1/1/1 0/0/0* 0/0/0* 0/0/0*
Adhesions scored
0–7
1/1/1 0/0/0* 1/1/1 0/0/0* 0/0/0* 1/1/2 1/1/1 1/1/1 0/0/0* 0/0/0* 0/0/0*
BPC 157 (10 μg/kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg) were applied alone and/or combined while controls received an equivolume of
saline (5 ml/kg) intraperitoneally.
*P<0.05, at least, vs. control
doi:10.1371/journal.pone.0162590.t001
Table 2. Brain lesions (scored 0–4, or 0–3, Min/Med/Max) in short bowel-rats and in short bowel-rats that received diclofenac (12 mg/kg
intraperitoneally).
Brain lesions
Brain edemascored
0–3
Massive small
bowel resection
Massive small bowel resection
Diclofenac
Balonized or red
neuronsscored 0–4
sali-
ne
BPC157 μg sali-
ne
BPC157 μg BPC
157 ng
L-NAME L-
arg
L-NAME
+L-arg
L-NAME
+BPC 157 μg
L-arg+BPC
157 μg
L-NAME+L-arg
+BPC 157μg
Edema 3/3/3 0/0/0* 3/3/3 1/1/1* 1/1/1* 3/3/3 2/2/
2*
3/3/3 1/1/2* 1/1/1* 1/1/2*
Cerebral 3/3/3 1/1/1* 3/3/3 1/1/1* 1/1/1* 4/4/4 2/2/
2*
3/3/3 1/1/2* 1/1/1* 1/1/2*
Cerebellar nn 2/2/2 1/1/1* 4/4/4 1/1/1* 1/1/1* 4/4/4 2/3/
3*
4/4/4 2/2/2* 2/2/2* 2/2/2*
Purkinje cells 1/1/1 0/0/0* 2/2/2 1/1/1* 1/1/1* 3/3/3 2/2/
2*
2/2/2 1/1/1* 1/1/1* 1/1/1*
Hippocam-pus 3/3/3 1/1/1* 3/3/3 1/1/1* 1/1/1* 4/4/4 2/2/
2*
3/3/3 1/1/1* 1/1/1* 1/1/1*
BPC 157 (10 μg/kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg) were applied alone and/or combined while controls received an equivolume of
saline (5 ml/kg) intraperitoneally.
*P<0.05, at least, vs. control.
doi:10.1371/journal.pone.0162590.t002
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Fig 1. Gross anastomosis assessment.Gross anastomosis was scored 1–4 (min/med/max) in untreated 24 h-short
bowel-rats (SBS) and those administered diclofenac (D, 12 mg/kg intraperitoneally). BPC 157 (Bμ and Bn, 10 μg/kg and
10 ng/kg, respectively), L-NAME (N, 5 mg/kg), and L-arginine (A, 100 mg/kg) were administered alone or combined while
controls received equivolume saline (5 mL/kg) intraperitoneally. *P<0.05, at least, vs. control.
doi:10.1371/journal.pone.0162590.g001
Fig 2. Microscopy of villus height, crypt depth, and inner and outer muscle layer adaptation I.Microscopical
assessment of villus height, crypt depth, and inner and outer muscle layer (means ± SD, μm) adaptation in 24 h-short
bowel-rats (SBS) administered diclofenac (D, 12 mg/kg intraperitoneally), BPC 157 (Bμ, 10 μg/kg) alone or combined, and
controls administered equivolume saline (5 mL/kg) intraperitoneally. *P<0.05, at least, vs. control.
doi:10.1371/journal.pone.0162590.g002
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Fig 3. Gross gastrointestinal lesion assessment in 24 h-short bowel-rats administered diclofenac. The sum of the
longest diameters of gross gastrointestinal (means ± SD) in 24 h-short bowel-rats (SBS) administered diclofenac (D, 12
mg/kg intraperitoneally). BPC 157 (Bμ and Bn, 10 μg/kg and 10 ng/kg, respectively), L-NAME (N, 5 mg/kg), and L-arginine
(A, 100 mg/kg) were administered alone or combined while controls were administered equivolume saline (5 mL/kg,
intraperitoneally. *P<0.05, at least, vs. control.
doi:10.1371/journal.pone.0162590.g003
Fig 4. Liver lesion assessment I. Liver lesions including necrosis, steatosis, and congestion were scored as 0–3 (min/
med/max), cell nuclei diameters (μm), area of cell cytoplasm (μm2), and double nuclei cell number (means ± SD) in
untreated 24 h-short bowel-rats (SBS) those administered diclofenac (D, 12 mg/kg intraperitoneally and BPC 157 (Bμ,
10 μg/kg) alone or combined and controls administered equivolume saline (5 mL/kg) intraperitoneally. *P<0.05, at least,
vs. control.
doi:10.1371/journal.pone.0162590.g004
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diclofenac and L-NAME were combined while this effect was ameliorated by the stablepenta-
decapeptide BPC 157 and attenuated to a lesser degree by L-arginine.
Short bowel and anastomosis presentation
As revealed 24 h after massive small intestine resection, anastomosis as well as gross and micro-
scopic presentations corresponded with ongoing adaptation in the remaining intestine.
(Table 1 and Figs 1, 2, 7, and 8).
Diclofenac was shown to worsen the poor gross anastomosis presentation (without gross
dehiscence), which was complicated by edema, increased inflammatory cells, and necrosis after
massive small intestine resectioning. In addition, this effect was even more intense in rats
administered diclofenac and L-NAME (Table 1, Fig 1). BPC 157 improved both gross and
microscopic presentation of anastomosis after massive small intestine resectioning and
completely counteracted the diclofenac-induced exacerbation in rats, as well as additional
aggravation in rats administered the combination of diclofenac and L-NAME. Furthermore, L-
arginine alone showed a beneficial effect on some assessed parameters. No further beneficial
effect was observed when BPC 157 and L-arginine coadministered. Indicatively, while L-argi-
nine reduced the L-NAME-aggravation to the levels of the diclofenac-controls, BPC 157 was
more effective, completely reversing the L-NAME-induced damage and anastomosis to normal
presentations.
More intense habitual adaptation occurred in all the intestinal layers of both the ileum and
jejunum in the remaining small intestine in rats administered BPC 157 (normally, ongoing
Fig 5. Bilirubin and liver enzymes assessment. Bilirubin and liver enzymes were measured (means ± SD) in untreated
24 h-short bowel-rats (SBS) and those administered diclofenac (D, 12 mg/kg intraperitoneally). BPC 157 (Bμ and Bn,
10 μg/kg and 10 ng/kg, respectively), L-NAME (N, 5 mg/kg), and L-arginine (A, 100 mg/kg) were administered alone or
combined and controls were administered equivolume saline (5 mL/kg) intraperitoneally. *P<0.05, at least, vs. control.
doi:10.1371/journal.pone.0162590.g005
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adaptation is greater in muscle layers than it is in the mucosa, Figs 2 and 8). In contrast, decay
appeared in rats administered diclofenac after the massive small intestine resectioning and this
limited ongoing adaptation was reversed. Following BPC 157 co-administration, the negative
diclofenac-reversal returned to the original BPC 157-mediated improved values in all intestinal
layers of both the ileum and jejunum of the remaining small intestines. Furthermore, consider-
ing the impaired adaptation following the massive small intestine resectioning in rats adminis-
tered diclofenac (Fig 7), L-arginine alone showed no effect but it lowered the L-NAME-
aggravation to levels that were similar to the diclofenac-control values. Indicatively, unlike the
diclofenac plus L-arginine-, diclofenac plus L-NAME-, and diclofenac plus L-NAME plus L-
arginine-treated rats, which showed no improvements, BPC 157 improved the diclofenac-
induced adaptation as well as the additional impairment caused by L-NAME in all of the wall
layers. No further beneficial effects were observed when BPC 157 and L-arginine were co-
administered.
Gastrointestinal lesions
Short-bowel rats habitually presented with small lesions in the stomach and duodenum
(2.5 ± 1.0 and 2.0 ± 1.0 mm, respectively), which were completely attenuated in rats adminis-
tered BPC 157. It is noteworthy that administration of diclofenac led to severe widespread
lesions in the whole gastrointestinal tract, stomach, duodenum, small intestine, and colon,
which were exacerbated following coadministration of diclofenac and L-NAME (Figs 3 and 11).
Interestingly, in massive small intestine resectioned and diclofenac-treated rats, L-arginine
alone showed no effects but appeared to antagonize the L-NAME-induced exacerbation (diclo-
fenac plus L-NAME plus L-arginine-treated rats exhibited lesions similar to those of
Fig 6. Brain lesion evaluations. Brain lesions were assessed in short bowel rats administered diclofenac (D, 12 mg/kg),
saline 5 mL/kg, or BPC 157 (10 μg/kg) intraperitoneally. Characteristic presentation of hippocampal (HC and HB) and
cerebellar nuclear (CC and CB) lesions are shown. Left upper panel (control, HC) shows severe edema and neuronal
damage (gray arrow indicates ballooned; black, edematous; and white, normal neurons); right upper panel (BPC 157, HB)
shows less edema and neuronal damage (gray arrow indicates ballooned; black, edematous; and white normal neurons).
Cerebellar nuclei, lower panel (control (HC) shows severe edema and neuronal damage (gray arrow indicates ballooned;
black, edematous; and white normal neurons); right lower (BPC 157, HB) shows less edema and neuronal damage (gray
arrow indicates ballooned; black, edema; and white, normal neurons), H&E, 40×.
doi:10.1371/journal.pone.0162590.g006
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diclofenac-treated rats). BPC 157, in all groups and all combinations consistently exhibited a
beneficial effect and in particular, appeared to nullify the effect of L-NAME, with lesions
markedly below diclofenac control values. No potentiation of the beneficial effect was observed
following coadministration of L-arginine and BPC 157.
Liver lesions, bilirubin levels, and enzyme activity
Liver lesions, bilirubin levels, and enzyme activity are presented in Figs 4, 5, 9, and Fig 10.
Short-bowel rats habitually presented with liver lesions (Figs 4 and 10) as well as increased
serum values of ALT, AST, and particularly bilirubin (Fig 5), which were all markedly exacer-
bated in rats administered diclofenac, and even more so in rats coadministered diclofenac and
L-NAME (Figs 5 and 9).
In general, BPC 157 improved symptoms in short-bowel rats by ameliorating the habitual
liver lesions, as well as completely reversing the diclofenac-induced exacerbation of liver lesions
and increased serum values of ALT, AST, and particularly bilirubin in all treated groups (BPC
157, 10 μg/kg and 10 ng/kg; L-NAME + BPC 157; L-arginine + BPC 157; and L-NAME + L-
arginine + BPC 157).
Furthermore, in diclofenac-treated rats, L-arginine alone showed a beneficial effect. No fur-
ther beneficial potentiation was observed when BPC 157 and L-arginine were coadministered.
Indicating that, while L-arginine reduced the L-NAME-induced aggravation to the values of
the diclofenac-controls, BPC 157 was more effective and completely reversed the L-NAME-
induced damage.
Fig 7. Microscopy of villus height, crypt depth, and inner and outer muscle layer adaptation II.Microscopical
assessment of villus height, crypt depth, and inner and outer muscle layer adaptation (means ± SD, μm) in 24 h-short
bowel-rats (SBS) treated with diclofenac (D, 12 mg/kg intraperitoneally). BPC 157 (Bμ and Bn, 10 μg/kg and 10 ng/kg,
respectively), L-NAME (N, 5 mg/kg), and L-arginine (A, 100 mg/kg) were administered alone or combined while controls
were administered equivolume saline (5 mL/kg) intraperitoneally. *P < 0.05 vs. control.
doi:10.1371/journal.pone.0162590.g007
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These effects can gradually exaggerate the only the mild stomach and duodenal mucosal
lesions that occur in massive small intestine resectioning. However, there is still evidence of mild
liver lesions as well as the already existing severe cerebral/hippocampal lesions. As the symptoms
were exacerbated with widespread severe lesions in the whole gastrointestinal tract, the liver
lesions were exacerbated as well. In addition, the aggravation of the cerebellar nuclea/Purkinje
cells lesions and the cerebral/hippocampus lesions were further aggravated in rats. All these
lesions (in particular, cerebral/Purkinje cells/hippocampus lesions) were even more intense in
rats coadministered L-NAME and diclofenac after massive small intestine resectioning.
Brain
The brain lesion evaluations are presented in Table 2 and Fig 6. Moderate and severe edema
(more often in the white matter) with red neurons (more often in the gray matter) without any
inflammatory reaction were also reduced by BPC 157 administration. Of note is the fact that
this beneficial effect was concomitant with an improvement in all intestinal layer post-resection
adaptation and lesions in the gastrointestinal tract and liver.
After a massive small bowel resection, Purkinje cells commonly appear to be least affected,
cerebellar nuclei are more affected, and cerebral cortical and hippocampal neurons are most
affected.
The combination of massive small bowel resectioning and diclofenac, enhanced their indi-
vidual toxicities as well and, therefore, the cerebellar nuclei, cerebral cortex, Purkinje cells, and
hippocampal neurons were all severely affected. These effects were further aggravated in rats
coadministered diclofenac and L-NAME (in particular, cerebral/Purkinje cells/hippocampal
lesions).
Fig 8. Microscopic presentation of intestinal adaptation in diclofenac-treated animals.Microscopic presentation of
intestinal adaptation in diclofenac-treated, controls (C), and BPC 157-treated (B) 24 h-short bowel rats. Upper left, control
(C) shows lower mean villus height and shallower crypt depth, H&E, 10×); upper right, BPC 157 (B) shows increased villus
height and crypt depth, H&E, 10×; lower panel, control (c) shows muscle thickness was less increased (H&E, 20×; and
lower panel, BPC 157 (B) shows muscle thickness was increased more H&E, 20×).
doi:10.1371/journal.pone.0162590.g008
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Of note, in diclofenac-treated rats, in all groups and combinations, BPC 157 consistently
exhibited a beneficial effect and in particular, might have nullified the effect of L-NAME with
lesions markedly below diclofenac-control values. Furthermore, in diclofenac-rats, L-arginine
alone showed a beneficial effect. Again, no further beneficial potentiation was observed when
BPC 157 and L-arginine were coadministered. However, L-arginine reduced the L-NAME-
induced aggravation to the values of the controls while BPC 157 was more effective than L-
arginine and completely reversed L-NAME-induced damage.
Therefore, taking the brain lesions as the end result, the reduction in brain lesions supports
the evidence that BPC 157 counteracted the deterioration from the onset. In addition, other
beneficial effects of BPC 157 administration were observed in different NSAID-induced brain
injuries [5–7].
Discussion
We have attempted to illustrate likely risks associated with major surgery and extended possi-
ble analgesic use in patients [2] including poor initial healing, lesions occurring in other organs
during the most critical early period, COX-blockade, and additional NOS-blockade, in a rat
model permitting acute evaluation within 24 hours. Thereby, during the period immediately
following surgery, short-bowel rats presented with gastrointestinal tract, liver, and brain
lesions, as well as failed anastomosis healing, intestinal adaptation aggravation by COX-block-
ade (diclofenac), and further exacerbation by additional NOS-blockade (diclofenac plus
L-NAME). In addition, we also sought to determine possible benefit of the use of the stable
Fig 9. Liver lesion assessment II. Liver lesion assessment revealed necrosis, steatosis, and congestion and was scored
as 0–3 (min/med/max), cell nuclei diameters (μm), area of cell cytoplasm (μm2), double nuclei cell number (means ± SD)
in untreated 24 h-short bowel-rats (SBS) and those administered diclofenac (D, 12 mg/kg intraperitoneally). BPC 157 (Bμ
and Bn, 10 μg/kg and 10 ng/kg, respectively), L-NAME (N, 5 mg/kg), and L-arginine (A, 100 mg/kg) were administered
alone or combined while controls were administered equivolume saline (5 mL/kg) intraperitoneally. *P < 0.05 vs. control.
doi:10.1371/journal.pone.0162590.g009
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gastric pentadecapeptide BPC 157 and NOS-substrate L-arginine [3,4], which have not been
previously shown.
Importantly, BPC 157 fully counteracted the lesions in rats subjected to massive resection-
ing combined with the effects of diclofenac and L-NAME. In addition, BPC 157 apparently
reduced all pernicious failure induced by the COX- and NOS-system in this early post-surgery
syndrome (diclofenac-, L-NAME-, diclofenac plus L-NAME-rats). This was in addition to the
previously observed beneficial effect shown in long-term short-bowel studies [1], as well as its
counteraction of NSAID-induced toxicity [4] and NOS-blockade [3].
The NO system may be specifically involved [3] in the L-arginine-induced the inhibition of
L-NAME-induced exacerbation of the symptoms. The more severe diclofenac plus L-NAME-
induced lesions were abrogated by L-arginine (to the diclofenac control level, diclofenac plus
L-NAME plus L-arginine-treated rats) (but not below the control values, which was achieved
with BPC 157 (diclofenac plus L-NAME plus BPC 157-treated rats)) rather than the regular diclo-
fenac lesions (mediated by COX inhibition and effects of diclofenac) which remained unopposed.
On the other hand, considering the similar mechanisms involved in modulating COX and
NOS inhibition [30–33], in the early short-bowel rats, diclofenac likely increased COX and
NOS inhibition, suggesting a further NOS-system failure [32,33]. This is an undesirable conse-
quence that occurred in conjunction with, and probably as a contributor to, the additional
widespread lesions in rats coadministered L-NAME and diclofenac, after massive small intes-
tine resectioning. In addition, the inhibition of high levels of NO by NOS inhibitors has been
found to decrease the production of prostaglandins in in vitro and ex vivomodels [31]. This
explains the previous evidence that BPC 157 might counteract the toxicity of various NSAIDs
[4–9], and ultimately counteract L-NAME-effects better than L-arginine does [3].
Fig 10. Liver lesions presentation. Liver lesions in short bowel rats administered diclofenac (12 mg/kg), saline 5 mL/kg,
or BPC 157 (10 μg/kg) intraperitoneally. Upper left panel, control (c) shows extensive microvesicular steatosis and
sinusoidal dilatation, H&E, 40×. Upper right panel, BPC 157 (B) shows less to no steatosis and minor sinusoidal dilatation
(circle) and more binucleated hepatocytes (H&E, 40×). Lower panel, control (c) shows occasional focal necrosis (arrow,
HE, 40×). Lower panel, BPC 157 (b) shows no necrosis, H&E, 40×.
doi:10.1371/journal.pone.0162590.g010
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Finally, the differential beneficial effects of BPC 157 (COX and NOS blockade), L-arginine
(NOS-blockade), and L-arginine-independent BPC 157 effects, might support the proposition
that BPC 157 and L-arginine may act via two separate NO system pathways as previously sug-
gested [3].
We have previously noted that the central nervous system is particularly vulnerable after
massive bowel resection surgery. This central defenselessness is likely more complex than pre-
viously believed. Furthermore, less gastrointestinal lesioning reduces the chances of toxins pen-
etrating the liver and brain [7]. The most severe lesions were noted in the cerebral and
hippocampal regions accompanied by fewer mucosal lesions in the stomach and duodenum
only, or mild (liver) lesions. These legions were exacerbated following treatment with diclofe-
nac (cerebellar/Purkinje cell) and definitively aggravated with L-NAME treatment. These
effects appear to be associated with the subsequent spreading lesions in the entire digestive
tract, increased liver lesions severity, and the events involved in the anastomosis. These events
included macro/microscopic necrosis, which were exacerbated more in rats administered diclo-
fenac alone or combined with L-NAME. Similarly, the already initiated (but limited) habitual
adaptation of the remaining small intestine was markedly attenuated and even reversed in
diclofenac-treated rats as well as in diclofenac and L-NAME-treated rats. Only BPC 157 consis-
tently (even with coadministration of diclofenac and L-NAME) rescued the rats from the anas-
tomosis, and vigorous intestine adaptation (villus height, crypt depth, inner muscular layer,
and outer muscular layers all vigorously adapted). In addition, the BPC 157-treated rats
showed fewer liver and brain lesions than the untreated rats did.
Finally, BPC 157 exhibited benefits specifically related to its molecular healing effects
[26–29] including stimulation of both the egr-1 gene and its repressor, Nab2, which could
Fig 11. Characteristic gross lesions in 24 h-short bowel-rats treated with diclofenac (small intestine and colon).
Characteristic gross lesion presentation in 24 h-short bowel-rats treated with diclofenac in the small intestine (left, +BPC
157, +saline, and +L-NAME) and colon (right, +BPC 157, +saline, and +L-NAME).
doi:10.1371/journal.pone.0162590.g011
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be part of a feedback mechanism that regulates egr-1-mediated gene transcription, cytokine
and growth factor generation, and early extracellular matrix (collagen) and blood vessels
formation [26–29]. Accordingly, BPC 157 might counteract various gastrointestinal [1,6–
8,14,15–20,30,34,35], liver [5–7,36–38], and brain [5–7,14,38,39] damages as previously
reviewed [3,4,10–13]. Furthermore, besides opposing the gastrointestinal tract, liver, and
brain lesions induced by NSAIDs [4–7] and NOS-blockade [3], there is evidence that BPC
157 antagonizes all stomach, liver, and brain associated lesions (including seizures) induced
by an overdose of insulin [38]. In this way, it also consistently opposes the associated gastroin-
testinal tract, liver, and brain lesion axis that is rapidly provoked after massive small bowel
resection.
Therefore, the BPC 157-mediated inhibition of the combined NSAID-toxicity and NOS-
blockade [3,4], likely counteracted the exaggerated risks associated with the surgery, the NO
system likely involved in the gastrointestinal [37] and liver damage, hepatic encephalopathy
[38], and the diclofenac-induced intestinal injury, in particular, mediated by the NO system
pathways [39]. The validation of hypothesis [3,4] would emphasize the beneficial effects of
BPC 157 and encourage its use in post-massive small bowel resection syndrome from the very
early stage, which would simultaneously revert the imbalance in both the dysfunctional prosta-
glandin and NO systems [3,4].
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